公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants , SGP 中国.江苏.无锡 Wuxi. Jiangsu . China 关于苏州新锐合金工具股份有限公司 2024 年年度报告 的信息披露监管问询函的核查意见 上海证券交易所科创板公司管理部： 苏州新锐合金工具股份有限公司（以下简称"新锐股份"或"公司"）于近 日收到上海证券交易所科创板公司管理部下发的上证科创公函【2025】0150 号 《关于苏州新锐合金工具股份有限公司 2024 年年度报告的信息披露监管问询函》 （以下简称"《问询函》"）。公证天业会计师事务所（特殊普通合伙）（以下 简称"年审会计师"或"公证天业"）作为新锐股份的年审会计师就《问询函》 有关问题逐项进行了认真核查，核查意见如下： 说明：在下述相关问题的回复中，若合计数与各分项数值相加之和在尾数上 存在差异，均为四舍五入所致。 问题 1：关于经营情况。年报披露，（1）公司 2024 年境内收入 10.31 亿 元，同比上升 34.56%，境外收入 7.82 亿元，同比上升 6.02%；境内毛利率 分点。（2） ...

Core Viewpoint - Narui Radar plans to acquire 100% equity of Tianjin Sigma Microelectronics for 370 million yuan, with a significant premium on the valuation based on the earnings method, indicating a strategic move to enhance its core radar technology capabilities [1][2]. Group 1: Acquisition Details - The acquisition price is set at 370 million yuan, with 50% (185 million yuan) to be paid in shares at an issuance price of 42.93 yuan per share, resulting in the issuance of 4.31 million shares [1]. - The assessed value of Tianjin Sigma's 100% equity is 371 million yuan, with an appraisal premium rate of 421.40% [1]. - The average price-to-earnings ratio for Tianjin Sigma's performance commitment is 14.23 times, significantly lower than the average of 69.62 times for comparable companies in the semiconductor MCU chip sector [1]. Group 2: Company Background and Strategic Intent - Narui Radar specializes in full-polarization active phased array radar technology and has been a pioneer in the industrialization of dual-polarization radar systems [1]. - The acquisition aims to vertically integrate the supply chain around Narui Radar's core business, enhancing the company's technological competitiveness and enabling a shift from component-level integration to chip-level collaboration [2]. - The integration of Tianjin Sigma's technology and resources is expected to improve the efficiency of next-generation high-performance radar development, responding to market demands [2]. Group 3: Financial Performance and Commitments - Tianjin Sigma is projected to achieve revenues of 102 million yuan and 123 million yuan in 2023 and 2024, respectively, with net profits of 4.22 million yuan and 12.39 million yuan [2]. - The acquisition includes a performance guarantee, with net profit commitments of no less than 22 million yuan, 25 million yuan, and 31 million yuan for the years 2025, 2026, and 2027, respectively, totaling a minimum of 78 million yuan over three years [2]. - The expected net profit growth for 2025 compared to 2024 is approximately 78% [2]. Group 4: Market Concerns - There are concerns regarding the feasibility of the performance commitments in the context of increasing competition in the global semiconductor industry and the rising number of domestic design firms [3]. - If performance targets are not met, Narui Radar may face a goodwill impairment risk of 253 million yuan [3]. - Notably, several shareholders of Tianjin Sigma are exiting prior to the acquisition, including those associated with iFlytek, raising questions about the transaction's stability [3].

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. is facing significant financial challenges, including a major loss attributed to credit impairment losses related to receivables from Guoyao Medicinal Materials Co., Ltd. [1][4] Group 1: Shareholder Actions - Huaren Century Group, a major shareholder, plans to reduce its stake in Huaren Pharmaceutical by up to 1% between June 24, 2025, and September 23, 2025, amounting to no more than 11,822,100 shares [1][2] - Huaren Century Group's shareholding has decreased from 53% in 2014 to 7.9% currently, following multiple rounds of share reductions [2][3] - Red Tower Innovation Investment Co., Ltd., the third-largest shareholder, has also been reducing its holdings, having sold 23,619,960 shares for a total of 74.16 million yuan from August 22, 2024, to April 29, 2025 [2] Group 2: Financial Performance - Huaren Pharmaceutical reported a net loss of 1.368 billion yuan for 2024, marking the worst performance since its listing in 2010, effectively erasing all profits accumulated over 13 years [3][4] - The company has cumulatively achieved a net profit of 1.197 billion yuan from 2010 to 2023, indicating that the loss in 2024 surpassed all previous profits [3] Group 3: Credit Impairment and Debt Recovery - The significant loss is primarily due to the full credit impairment of receivables amounting to 1.3478 billion yuan owed by Guoyao Medicinal Materials [4][6] - Huaren Pharmaceutical's subsidiary, Qingdao Huaren Pharmaceutical Co., Ltd., had established a business relationship with Guoyao Medicinal Materials, resulting in 1.41 billion yuan in receivables [4][5] - A repayment agreement was signed in January 2024, allowing Guoyao Medicinal Materials three years to settle the debt, but the execution of this agreement remains uncertain [6] Group 4: Guoyao Medicinal Materials' Issues - Guoyao Medicinal Materials is not controlled by the state-owned China National Pharmaceutical Group, despite its name, and has faced various operational issues [5][6] - The company has multiple enforcement actions against it, totaling 106 million yuan, and has been subject to numerous restrictions and judgments [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603388 证券简称：*ST元成（维权） 公告编号：2025-056 元成环境股份有限公司 关于转让控股子公司硅密电子股权及业绩补偿进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 元成环境股份有限公司（以下简称"公司"）前期收购硅密（常州）电子设备有限公司（以下简称"硅 密电子"或"交易标的"）51%股权，2024年因公司资金流动性面临重大挑战，未能按照约定及时支付股 权转让进度款，因此2025年1月 YOYODYNE,INC.提起诉讼并主张了损失赔偿，同时硅密电子存在2024 年度业绩承诺无法完成的情况。结合行业竞争、市场环境、经营管理等方面的不确定因素，公司决定向 YOYODYNE,INC.转让硅密电子51%股权，本次股权转让价格按评估价进行转让，硅密电子51%股权对 应评估价值为9,333.00万元。本次股权转让有利于公司及时止损，降低投资运营风险，集中优势资源， 聚焦主营业务加速发展；也为公司减轻了支付股权转让款的压力、降低了 ...

Core Viewpoint - The company has undergone significant restructuring to address previous internal control deficiencies, including related party fund occupation and illegal guarantees, leading to a positive outlook for its financial stability and operational continuity. Group 1: Internal Control and Audit Findings - The company received a negative internal control audit opinion in 2023 due to unresolved issues related to related party fund occupation and illegal guarantees [2][3] - The company has completed the necessary rectifications and received a standard unqualified opinion for its internal control audit for 2024, indicating effective internal controls [6][7] - The audit procedures included testing the effectiveness of internal controls related to fund management and contract approval processes, with a minimum testing frequency established [4][5] Group 2: Financial Performance and Restructuring - The company’s asset-liability ratio improved from 107.32% at the end of 2023 to 74.44% at the end of 2024, indicating a significant reduction in debt levels [8] - The company reported a narrowed net loss of CNY 77.01 million in Q1 2025 compared to a loss of CNY 186.87 million in Q1 2024, suggesting a recovery in operations [8] - Cash and cash equivalents at the end of 2024 and Q1 2025 were CNY 123.38 million and CNY 825.66 million, respectively, indicating sufficient liquidity for operations [8] Group 3: Compliance and Regulatory Matters - The company has resolved previous non-operating fund occupation and illegal guarantee issues through its restructuring plan, with no new incidents reported in 2024 [7][10] - The company has complied with the requirements set by the China Securities Regulatory Commission (CSRC) regarding previous financial misstatements, and the impact of these issues has been eliminated [12][19] - The company has submitted an application to lift the delisting risk warning, asserting compliance with relevant stock exchange rules [13][19] Group 4: Asset Impairment and Losses - The company reported a total asset impairment loss of CNY 88.99 million for the reporting period, including inventory and fixed asset impairments [21][22] - Specific reasons for credit impairment losses were detailed, including issues with customer payments and project compliance [22][23] - The company has taken a cautious approach in recognizing impairment losses, reflecting ongoing challenges in the market and customer relationships [22][24]

兖州东方机电有限公司 审计报告书 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 目 录 一、审计报告 二、审计报告附送 三、审计报告附件 中兴华会计师事务所（特殊普通合伙） 地 址 （ l o c a t i o n ）： 北 京 市 丰 台 区 丽 泽 路 2 0 号 丽 泽 S O H O B 座 20 层 1 6 电 话 （ t e l ）： 0 1 0 - 5 1 4 2 3 8 1 8 传 真 （ f a x ）： 0 1 0 - 5 1 4 2 3 8 中兴华审字（2025）第 030588 号 兖州东方机电有限公司全体股东： 一、审计意见 我们审计了兖州东方机电有限公司（以下简称"东方机电"）财务报表，包括 变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公 允反映了东方机电 2024 年 12 月 31 日财务 ...

Group 1 - The core point of the article is that Jiyuan Holdings Group Co., Ltd. (*ST Jiyuan) will be delisted from the Shenzhen Stock Exchange on May 29, 2025, due to triggering mandatory delisting rules after its stock price remained below 1 yuan for 20 consecutive trading days [1][3] - The company has experienced continuous losses since 2019, with a cumulative net profit loss exceeding 3.2 billion yuan from 2019 to 2023 [3] - Jiyuan Holdings has faced significant goodwill impairment risks, totaling over 1.5 billion yuan from 2019 to 2024, which has directly contributed to its net profit losses [3] Group 2 - The company was originally known as Tonghua Shuanglong Chemical Co., Ltd. and transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical [3] - Since its rebranding in 2017, the company has aggressively pursued mergers and acquisitions, acquiring over ten companies within three years, leading to a dual business model of "chemicals + pharmaceuticals" [3] - In 2024, the company's revenue declined by 3.69%, and its losses expanded to 439 million yuan [3] Group 3 - As of 2025, a total of 11 companies have been delisted from the A-share market, with *ST Jiyuan being one of them, alongside others like *ST Meixun and *ST Bo Xin [4] - The reasons for delisting include breaches of face value, market value, voluntary delisting applications, and forced delisting due to major violations [4]

Core Viewpoint - Jiyuan Holdings Group Co., Ltd. has been announced to be delisted from the Shenzhen Stock Exchange due to its stock price falling below 1 yuan for twenty consecutive trading days, with the delisting effective on May 29, 2025 [1] Group 1: Company Performance and Financials - Jiyuan Holdings, originally a chemical company, transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical, establishing a dual business model of "chemicals + pharmaceuticals" [3] - The company engaged in aggressive acquisitions, acquiring over ten companies within three years, with its pharmaceutical segment accounting for 70% of total revenue at its peak, leading to a market capitalization exceeding 5 billion yuan [3] - However, the acquired companies' performance deteriorated post-acquisition, with Zhejiang Yalida Gelatin Co., Ltd. reporting a 94% drop in net profit in 2019, and Changchun Puhua Pharmaceutical Co., Ltd. incurring direct losses [3] - Since 2019, Jiyuan Holdings has been in a continuous loss state, accumulating losses exceeding 3.7 billion yuan [4] Group 2: Attempts at Restructuring and Ownership Changes - The company has made several attempts to change ownership in response to its financial struggles, but all efforts have failed [5] - In 2019, an agreement to transfer shares to Jilin Jisheng Asset Management was terminated due to disagreements on key terms [5] - A proposed acquisition of Xiu Zheng Pharmaceutical was also abandoned due to regulatory uncertainties, leading to scrutiny from the Shenzhen Stock Exchange [5][6] - In 2020, a deal to transfer control to Ben Cao Hui Pharmaceutical faced disputes over payment, resulting in legal proceedings [6]

星标 ★ IPO日报 精彩文章第一时间推送 5月28日晚间，吉药控股集团股份有限公司（300108.SZ，下称"*ST吉药"）发布公告称，公司股 票已被深圳证券交易所决定终止上市，将在2025年5月29日被摘牌。公司股票因触及交易类强制退 市情形被本所作出终止上市决定，不进入退市整理期。 AI制图 回顾公司退市流程，4月23日晚间，公司披露称， 截至2025年4月23日，公司因股票连续20个交 易日收盘价低于1元，触发深交所终止上市规则，公司股票将被终止上市。公司股票将于4月24日 开市起停牌。 5月26日，公司收到深交所《关于吉药控股集团股份有限公司股票终止上市的决定》，深交所决定 终止公司股票上市。 据悉，公司前身为通化双龙化工股份有限公司，主营国防化工用白炭黑生产。2014年通过收购金 宝药业转型医药领域，形成"化工+医药"双主业模式。 2017年更名为吉药控股后，公司便开启了激进并购的模式，三年内收购普华制药、亚利大胶丸等 十余家企业，业务覆盖医药工业、商业、研发等八大板块。 记者 吴鸣洲 文字编辑 褚念颖 版面编辑 光云 更多精彩 然而，不断的跨界扩张带来了大额的商誉风险， 2019年至2024年， ...

Company Overview - Tongling Jieya Biotechnology Co., Ltd. was established in 1999 and specializes in the research, production, and sales of wet wipes, with over 20 years of industry experience [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2]. - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 10.06 million yuan [2]. Q&A Highlights - **Impact of Tariffs**: The current tariff policies have a relatively limited impact on the company's overall business [3]. - **US Wet Wipe Factory Project**: The project is currently under construction and is expected to commence production next year [3]. - **Kimberly-Clark European Orders**: Production began in April 2025, and order deliveries are progressing as planned [3]. - **Asset Impairment**: The company adheres to accounting standards and will reasonably assess asset impairment based on prudence [3]. - **Self-Branding Considerations**: The company is exploring self-branding through an industrial fund but has seen low revenue conversion rates [3]. - **Facial Mask Business Outlook**: Currently serving major clients like L'Oréal and Galen Group, with a gradual expansion to other domestic brands, though new client orders are relatively small [3]. - **Jiechuang Medical Subsidiary**: The subsidiary is undergoing strategic adjustments, with cautious investment based on overall business layout and resource optimization [3]. - **Equity Incentives**: The company is focused on establishing long-term incentive mechanisms and will disclose plans as they develop [3]. - **Compliance with Regulations**: The company conducted the investor communication event in accordance with regulatory guidelines, ensuring no undisclosed significant information leaks occurred [3].